| Symbol | BIAFW |
|---|---|
| Name | BIOAFFINITY TECHNOLOGIES, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Commercial Physical & Biological Resarch |
| Address | 3300 NACOGDOCHES ROAD,SUITE 216, SAN ANTONIO, Texas, 78217, United States |
| Telephone | +1 210 - 698-5334 |
| Fax | — |
| — | |
| Website | https://www.bioaffinitytech.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | — |
| Description | bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company is involved in developing technologies that, in the future, will be able to detect and monitor diseases of the lung and other cancers and treat many cancers. Additional info from NASDAQ: |
bioAffinity Technologies Launches New Study To Expand Use ofCyPath® Lung Technology for Asthma and COPD Diagnosis and Treatment
Read morebioAffinity Technologies Launches New Study To Expand Use of CyPath® Lung Technology for Asthma and COPD Diagnosis and Treatment
Read more(99% Neutral) BIOAFFINITY TECHNOLOGIES, INC. (BIAFW) Provides Update on diagnostics for lung cancer SAN ANTONIO
Read moreNew Case Study: bioAffinity Technologies’ CyPath® Lung Diagnostic Supports Physician’s Assessment, Prompts Follow-Up Imaging and Defers Unnecessary Biopsy
Read moreNew Case Study: bioAffinity Technologies’ CyPath® Lung Diagnostic Supports Physician’s Assessment, Prompts Follow-Up Imaging and Defers Unnecessary Biopsy
Read more(50% Neutral) BIOAFFINITY TECHNOLOGIES, INC. (BIAF) Provides Update on cancer for panel on lung nodule management SAN ANTONIO
Read morebioAffinity Technologies’ CyPath® Lung to Be Featured at Cleveland Clinic Annual “Advances in Early Lung Cancer Detection” Symposium April 16
Read morebioAffinity Technologies’ CyPath® Lung to Be Featured at Cleveland Clinic Annual “Advances in Early Lung Cancer Detection” Symposium April 16
Read more(70% Positive) BIOAFFINITY TECHNOLOGIES, INC. (BIAFW) Announces Clinical Development Update
Read morebioAffinity Technologies’ CyPath® Lung Test Unit Sales Surged 146% Year-Over-Year in Q1 2026
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07168993 | Evaluate the Clinical Performance of the Flow Cytometry - FlowPath Lung Test as… | Na | Lung Cancer (Diagnosis) | Recruiting | 2026-02-25 | 2029-07-01 | ClinicalTrials.gov |
| NCT05870592 | Detection of Abnormal Respiratory Cell Populations in Lung Cancer Screening Pat… | — | Lung Cancer | Unknown | 2023-08-01 | 2024-06-01 | ClinicalTrials.gov |
| NCT03457415 | Collection of Sputum and Labeling for Lung Cancer | — | Lung Cancer | Recruiting | 2018-03-01 | 2025-12-01 | ClinicalTrials.gov |
| NCT03837600 | Sputum Labeling Utilizing Synthetic Meso-Tetra (4-Carboxyphenyl) Porphyrin (TCP… | — | Lung Cancer | Completed | 2016-09-22 | 2018-08-15 | ClinicalTrials.gov |
| NCT02388074 | Sputum Labeling Utilizing Synthetic Meso-Tetra (4-Carboxyphenyl) Porphine (TCPP… | Na | Lung Cancer | Completed | 2015-03-01 | 2015-04-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Standard medical treatment | OTHER | Approved | Lung Cancer (Diagnosis) | RECRUITING | NCT07168993 |
| CyPath® | DEVICE | Approved | Lung Cancer | COMPLETED | NCT02388074 |